Navigation Links
Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
Date:5/3/2012

LANCASTER, Pa. and ROCKVILLE, Md., May 3, 2012 /PRNewswire/ -- Immunomic Therapeutics, Inc., ("ITI," Lancaster, PA) a privately-held biotechnology company with laboratories in Rockville, MD, announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug Application ("IND") filed for the allergy immunotherapy, JRC- LAMP-vax.  On April 12th, the FDA notified ITI that there will be no clinical hold and that ITI may now proceed with its clinical trial in June for JRC-LAMP-vax in Atlanta with subjects sensitive to Japanese Red Cedar pollen.

JRC-LAMP-Vax is a plasmid-based DNA vaccine that will be studied for the treatment of patients with rhino-conjunctivitis (runny nose) symptoms caused by allergic reaction to Japanese red cedar pollen. Almost 45% of the Japanese people are allergic to Japanese red cedar pollen. In North America, there is allergic rhinitis to mountain cedar pollen, which is 80% cross-reactive with Japanese red cedar pollen allergen.  ITI intends to partner with a Japanese pharmaceutical company for studies in Japan and will seek FDA approval of the vaccine in the US.

ITI provided FDA with animal studies of JRC-LAMP-Vax, showing no alteration of the routine clinical pathology, body weight, food consumption, temperature, ophthalmology, dermal irritation or the histopathology of any tissue examined microscopically. Overall, JRC-LAMP-Vax caused no abnormal safety issues in bio-distribution and toxicology studies in animals. This data was consistent with other reported animal and human studies of components of its vaccine.

Animal safety studies and human clinical studies have documented that LAMP DNA vaccine induces a protective antibody immune response consistent with a preferential MHC-II immune system presentation induced by the LAMP component. LAMP-based vaccines hold potential
'/>"/>

SOURCE Immunomic Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Regulus Therapeutics Appoints Bruce Carter to its Board of Directors
3. Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
4. Echo Therapeutics to Present Positive Clinical Trial Results at the 72nd Scientific Sessions of the American Diabetes Association
5. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
6. Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORAâ„¢ Oral Calcitonin
7. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
8. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
9. Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
10. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
11. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Los Angeles, CA (PRWEB) February 26, 2015 ... organizing an online demonstration to support life extension technologies ... to 8pm UTC, Universal Coordinated Time, on March 21st ... around the world. , Eric Schulke, Founder of ... we must act with urgency. The Movement for Indefinite ...
(Date:2/26/2015)... The Pittcon 2015 Exposition, which takes ... Morial Convention Center in New Orleans, Louisiana, will ... 2015) displaying products and services used by the ... The Exposition will offer the latest innovations in ... chemistry; drug discovery; nanotechnology; life sciences to include ...
(Date:2/26/2015)... Feb. 26, 2015  Dyadic International, Inc. ("Dyadic") ... and proprietary technologies are used to develop, manufacture ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... results for year ending December 31, 2014 after ... will host a conference call that day at ...
(Date:2/26/2015)... THE WOODLANDS, Texas , Feb. 26, 2015   ... today that Lexicon management will present at the Cowen 35 ... 2015 at 8:40 a.m. EST in Boston ... development programs and milestones. A webcast of the ... . An archived version of the presentation will be available ...
Breaking Biology Technology:Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3Pittcon 2015 Announces Exposition Highlights 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Lexicon To Present At The Cowen 35th Annual Health Care Conference 2
... S.C., Aug. 6 Denham Capital,("Denham") announced ... $60 million in VitAG,Corporation ("VitAG"). VitAG technology ... product capable of competing with and,outperforming conventional ... multiple biosolids-to-fertilizer manufacturing plants., "Denham,s investment ...
... Million; GAAP EPS $0.53; Adjusted EPS $0.48, CORONA, ... ), a leading specialty pharmaceutical,company, today reported financial results ... Quarter 2008 Results, Net revenue for the second ... million, or $0.53 per diluted share. Net income for ...
... on Tuesday, August 12, 2008, ROCKVILLE, Md., ... a clinical-stage pharmaceutical company developing,therapeutics for the treatment ... for the three and six-month periods ending June,30, ... The Company reported a net loss for the ...
Cached Biology Technology:Denham Capital to Invest $60 Million in VitAG, Recycler of Municipal Biosolids 2Watson Pharmaceuticals Reports Second Quarter 2008 Results 2Watson Pharmaceuticals Reports Second Quarter 2008 Results 3Watson Pharmaceuticals Reports Second Quarter 2008 Results 4Watson Pharmaceuticals Reports Second Quarter 2008 Results 5Watson Pharmaceuticals Reports Second Quarter 2008 Results 6Watson Pharmaceuticals Reports Second Quarter 2008 Results 7Watson Pharmaceuticals Reports Second Quarter 2008 Results 8Watson Pharmaceuticals Reports Second Quarter 2008 Results 9Watson Pharmaceuticals Reports Second Quarter 2008 Results 10Watson Pharmaceuticals Reports Second Quarter 2008 Results 11Watson Pharmaceuticals Reports Second Quarter 2008 Results 12Watson Pharmaceuticals Reports Second Quarter 2008 Results 13Watson Pharmaceuticals Reports Second Quarter 2008 Results 14Watson Pharmaceuticals Reports Second Quarter 2008 Results 15Watson Pharmaceuticals Reports Second Quarter 2008 Results 16Watson Pharmaceuticals Reports Second Quarter 2008 Results 17EntreMed Reports Second Quarter 2008 Financial Results 2EntreMed Reports Second Quarter 2008 Financial Results 3EntreMed Reports Second Quarter 2008 Financial Results 4EntreMed Reports Second Quarter 2008 Financial Results 5
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... that it has been named an American Society ... Center of Excellence. The ASMBS Center of ... track record of favorable outcomes in bariatric surgery. ... of our experienced surgeons and our institutional commitment ...
... lakes and even wet soil, diatoms are unicellular algae ... these tiny phytoplankton could be harboring the next big ... walls by laying down submicron-sized lines of silica, a ... industrysilicon. If we can genetically control that process, we ...
... study by the University of Exeter has highlighted ... for conservation projects. Published online in the journal ... rates of captive carnivores that are released into ... three captive-born carnivores survives in the wild, with ...
Cached Biology News:Pennsylvania Hospital recognized for excellence in bariatric surgery 2In diatom, scientists find genes that may level engineering hurdle 2Captive carnivores not up to wild living 2
... Re-Blot Western Blot Recycling Kit is ... Western blots that have been developed ... other isotopes. It is not recommended ... 4-chloronapthol, etc.), as it is not ...
Applications: Western blotting ...
... Series of positioning slides offers multiple ... leadscrew, micrometer, and manual. With this ... cost-effective multi-axis systems. These slides also ... resolutions down to 10 nanometers, integrated ...
...
Biology Products: